logo
Twitter
Discord
Email
logo
Anixa Biosciences, Inc.

Anixa Biosciences, Inc.

NASDAQ•ANIX
CEO: Dr. Amit Kumar Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 1983-10-07
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Contact Information
3150 Almaden Expressway, Suite 250, San Jose, CA, 95118, United States
408-708-9808
www.anixa.com
Market Cap
$106.47M
P/E (TTM)
-9.5
38.2
Dividend Yield
--
52W High
$5.46
52W Low
$2.33
52W Range
27%
Rank52Top 73.5%
2.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.08-127.20%
4-Quarter Trend

FCF

-$1.26M+35.38%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Operating Loss Narrows Nine-month loss from operations reduced to $8.825M USD, improving from $10.668M USD loss previously reported.
R&D Spending Decreases Nine-month R&D expenses fell $991K USD to $3.929M USD, driven by lower outside research costs for both programs.
Liquidity Position Maintained Total cash, equivalents, and short-term investments stood at $16.029M USD as of July 31, 2025, sufficient for twelve months.
Equity Raised via ATM Raised $1.924M USD net proceeds during nine months via at-the-market equity offering; $95M capacity remains available.

Risk Factors

Continued Zero Revenue No revenue generated from therapeutics or vaccine programs to date; profitability relies on distant future licensing agreements.
Cash Burn Continues Total cash, equivalents, and short-term investments decreased by $3.895M USD over nine months, reflecting ongoing operational cash usage.
High Stock-Based Costs Stock-based compensation expense totaled $2.822M USD for nine months, impacting reported operating results significantly.
Clinical Trial Uncertainty Future success depends on positive results from ongoing Phase 1 trials; Phase 2 initiation requires FDA consultation post-data release.

Outlook

Breast Vaccine Data Expected Anticipate reporting final Phase 1 data for breast cancer vaccine at San Antonio Breast Cancer Symposium in December 2025.
Prepare Phase Two Trial Preparing to initiate Phase 2 trial for breast cancer vaccine in neo-adjuvant setting following final Phase 1 data review.
Focus on Therapeutics Development Expect development of therapeutics and vaccines to remain primary focus over next several quarters; patent licensing is secondary.
CAR-T Trial Escalation CAR-T dose escalation trial continues, determining maximum tolerated dose across intravenous and intraperitoneal delivery arms.

Peer Comparison

Revenue (TTM)

C4 Therapeutics, Inc.CCCC
$30.11M
-10.6%
Nuvectis Pharma, Inc.NVCT
$26.80M
-753.4%
Cardiff Oncology, Inc.CRDF
$501.00K
-27.3%

Gross Margin (Latest Quarter)

C4 Therapeutics, Inc.CCCC
100.0%
+13.4pp
Cardiff Oncology, Inc.CRDF
100.0%
+0.0pp
Anixa Biosciences, Inc.ANIX
0.0%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CYBN$413.02M-2.6-51.8%15.9%
GLSI$344.43M-17.4-1042.8%0.0%
NVCT$217.21M-7.6-141.9%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 9, 2026
|
EPS:-
|
Revenue:-
Reports
All Years
  • Form 10-K - FY 2025

    Period End: Oct 31, 2025|Filed: Jan 12, 2026|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.34+12.8%
    N/A
  • Form 10-Q - Q3 2025

    Period End: Jul 31, 2025|Filed: Sep 10, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.07-30.5%
    N/A
  • Form 10-Q - Q2 2025

    Period End: Apr 30, 2025|Filed: May 28, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.09-12.0%
    N/A
  • Form 10-Q - Q1 2025

    Period End: Jan 31, 2025|Filed: Mar 11, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.10-1.1%
    N/A
  • Form 10-K - FY 2024

    Period End: Oct 31, 2024|Filed: Jan 10, 2025|
    Revenue: $0.00-100.0%
    |
    EPS: $-0.39-21.9%
    N/A
  • Form 10-Q - Q3 2024

    Period End: Jul 31, 2024|Filed: Sep 6, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.10+23.3%
    N/A
  • Form 10-Q - Q2 2024

    Period End: Apr 30, 2024|Filed: Jun 4, 2024|
    Revenue: $0.00-100.0%
    |
    EPS: $-0.10+49.5%
    N/A
  • Form 10-Q - Q1 2024

    Period End: Jan 31, 2024|Filed: Mar 12, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.10+45.8%
    N/A